Document is current
Any future updates will be listed below
-
Authors
Tosoian, Jeffrey J.
Birer, Samuel R.
Jeffrey Karnes, R.
Zhang, Jingbin
Davicioni, Elai
Klein, Eric E. http://orcid.org/0000-0002-1783-0698
Freedland, Stephen J.
Weinmann, Sheila
Trock, Bruce J.
Dess, Robert T. http://orcid.org/0000-0003-2331-3758
Zhao, Shuang G.
Jackson, William C.
Yamoah, Kosj
Dal Pra, Alan
Mahal, Brandon A.
Morgan, Todd M. http://orcid.org/0000-0002-1140-0603
Mehra, Rohit http://orcid.org/0000-0002-6955-8884
Kaffenberger, Samuel
Salami, Simpa S.
Kane, Christopher
Pollack, Alan
Den, Robert B.
Berlin, Alejandro http://orcid.org/0000-0002-1880-6905
Schaeffer, Edward M.
Nguyen, Paul L.
Feng, Felix Y.
Spratt, Daniel E. http://orcid.org/0000-0002-5973-4741
-
Funding
Funding for this research was provided by:
Prostate Cancer Foundation
U.S. Department of Defense (PC151068)
U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute (P50CA186786)
- License Information
-
More Information
Article History
Received: 28 October 2019
Revised: 24 January 2020
Accepted: 9 March 2020
First Online: 30 March 2020
Compliance with ethical standards
:
: Nonrelevant conflicts of interest will be disclosed in the ICMJE forms. JJT: Leadership role with equity interest: LynxDx, Inc. SJF: Research funding: Decipher Biosciences. SGZ: Travel/expenses and patent applications pending with Decipher Biosciences. TMM: Research funding: Myriad Genetics, GenomeDx. EMS: Consultant: Abbvie. DES: Advisory board: Blue Earth,Janssen, and AstraZenica. Funding: Janssen.
